Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 10/20 | 0.53 |
| ▸ | NMBR | P28336 | 2/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788691 | 0.92 | NTSR2 (0.55) | NTSR2NTSR1SORT1OPRD1CAPN1 | |
| SCHEMBL30933157 | 0.92 | CXCR4 (0.54) | GRPRNMBRNTSR2NTSR1SORT1 | |
| SCHEMBL5497927 | 0.91 | CXCR4 (0.60) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29776260 | 0.91 | DPP3 (0.49) | NTSR2NTSR1SORT1CTSLCTSS | |
| SCHEMBL29904119 | 0.89 | MAGI3 (0.52) | GRPRNMBRNTSR1CAPN1CTSB | |
| SCHEMBL29800522 | 0.88 | CXCR4 (0.51) | GRPRNMBRNTSR2NTSR1SORT1 | |
| SCHEMBL30933128 | 0.87 | CXCR4 (0.56) | NTSR2NTSR1SORT1CXCR4 | |
| SCHEMBL21949223 | 0.87 | NTSR2 (0.52) | GRPRNMBRNTSR2NTSR1SORT1 | |
| SCHEMBL30608599 | 0.87 | GRPR (0.55) | GRPRNMBRCAPN1CTSBCXCR4 | |
| SCHEMBL22018326 | 0.86 | NTSR2 (0.51) | GRPRNMBRNTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
| EP-1409017-A4 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1409017-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | Drug Innovation & Design, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | DRUG INNOVATION & DESIGN, INCORPORATED | 2003-02-13 | — | — | US | disclosed |
| WO-2003000201-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN, INCORPORATED (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | EPHA2, EEA1, TPX2 | GRPR 3719/4885NMBR 2044/4885NTSR2 2181/4885 |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | GRPR 3708/4885NMBR 1869/4885NTSR2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.